Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Women's issues in mood disorders.

P J Goodnick1, T Chaudry, J Artadi

  • 1Department of Psychiatry & Behavioural Sciences, University of Miami, School of Medicine, D79, 1400 NW 10 Avenue, Ste 304A, Miami, FL 33136, USA. pgoodnick@aol.com

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long term effect of Mediterranean diet on weight loss.

Nutricion hospitalaria·2010
Same author

Depression in the new millennium.

CNS spectrums·2008
Same author

Psychopharmacology of depression in the next millennium.

CNS spectrums·2008
Same author

Renal artery stenosis in renal transplantation presentation and management.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2008
Same author

Antipsychotic medication: effects on regulation of glucose and lipids.

Expert opinion on pharmacotherapy·2002
Same author

Ziprasidone: profile on safety.

Expert opinion on pharmacotherapy·2002
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Selective serotonin reuptake inhibitors (SSRIs) show promise for treating women's specific mood disorders like PMDD, PPD, and PMD. SSRIs may be more effective in women than older antidepressants, with some options safe for pregnancy.

Area of Science:

  • Pharmacology
  • Women's Health
  • Neuroscience

Background:

  • Historically, antidepressant research overlooked gender-specific applications.
  • Recent focus on selective serotonin reuptake inhibitors (SSRIs) has highlighted gender differences in antidepressant efficacy and side effects.
  • Women experience unique reproductive-related mood disorders, including premenstrual dysphoric disorder (PMDD), postpartum depression (PPD), and perimenopausal depression (PMD).

Purpose of the Study:

  • To review the efficacy and safety of antidepressants, particularly SSRIs, in women.
  • To address gender-specific considerations in antidepressant pharmacotherapy.
  • To examine the management of women-specific mood disorders and challenges during pregnancy and lactation.

Main Methods:

  • Review of existing literature on antidepressant use in women.

Related Experiment Videos

  • Comparative analysis of SSRI efficacy versus older tricyclic antidepressants (TCAs).
  • Examination of hormonal effects (e.g., prolactin) and teratogenic risks.

    • Main Results:

    • SSRIs demonstrate potentially greater efficacy in women compared to TCAs.
    • SSRIs are effective for PMDD, PPD, and PMD, with intermittent treatment options for PMDD.
    • SSRIs, particularly fluoxetine and sertraline, show supportive data for safe use in early pregnancy.
    • Most SSRIs can increase prolactin levels, potentially causing amenorrhea and osteoporosis, except sertraline.
    • Sertraline's unique dopamine reuptake inhibition may offer benefits for sleep and memory.
    • Women with bipolar disorder face increased relapse risks during pregnancy and postpartum, with considerations for mood stabilizer use.

    Conclusions:

    • SSRIs represent a significant advancement in treating women's mood disorders, offering improved efficacy and targeted treatments.
    • Careful consideration of hormonal side effects and pregnancy risks is crucial when selecting antidepressants for women.
    • Sertraline presents a distinct profile with potential advantages regarding hyperprolactinemia, sleep, and memory.
    • Management of mood disorders in women, especially with bipolar disorder, requires tailored approaches considering pregnancy and lactation.